Drugs / ASP1650
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03760081 | Mar 2019 → Oct 2020 | malignant germ cell tumor | Astellas Pharma Global Development, Inc. | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP1650 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03760081 ↗ |
| Modality | Monoclonal antibody | “a Monoclonal Antibody Targeting Claudin 6 (CLDN6)” NCT03760081 ↗ |
| Route | Intravenous | “as intravenous infusion” NCT03760081 ↗ |
| Target | CLDN6 | “ASP1650 is a chimeric-mouse/human-IgG1 antibody directed against CLDN6.” PMID 35759134 ↗ Jun 2022 |